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HIV-1 infection is characterized by varying degrees of chronic
immune activation and disruption of T-cell homeostasis, which
impact the rate of disease progression. A deeper understanding of
the factors that influence HIV-1–induced immunopathology and
subsequent CD4+ T-cell decline is critical to strategies aimed at
controlling or eliminating the virus. In an analysis of 127 acutely
infected Zambians, we demonstrate a dramatic and early impact of
viral replicative capacity (vRC) on HIV-1 immunopathogenesis that
is independent of viral load (VL). Individuals infected with high-RC
viruses exhibit a distinct inflammatory cytokine profile as well
as significantly elevated T-cell activation, proliferation, and CD8+
T-cell exhaustion, during the earliest months of infection. More-
over, the vRC of the transmitted virus is positively correlated with
the magnitude of viral burden in naive and central memory CD4+
T-cell populations, raising the possibility that transmitted viral
phenotypes may influence the size of the initial latent viral reser-
voir. Taken together, these findings support an unprecedented
role for the replicative fitness of the founder virus, independent
of host protective genes and VL, in influencing multiple facets of HIV-
1–related immunopathology, and that a greater focus on this param-
eter could provide novel approaches to clinical interventions.
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From the start of the AIDS epidemic, HIV-1 infection hasbeen characterized by a steady decline in CD4+ T cells that
results in a state of overt immunodeficiency marked by an increased
susceptibility to opportunistic infections and malignancies (1). Al-
though a majority of HIV-1–infected individuals eventually prog-
ress to AIDS during their lifetime, they do so at drastically different
rates (2). Several immunological abnormalities during HIV-1 in-
fection have been identified that correlate with disease progression,
such as a rapid and robust expression of proinflammatory cytokines,
chronic immune activation, cellular exhaustion, and infection of
vulnerable memory CD4+ T-cell subsets important for maintaining
T-cell homeostasis (3). The degree to which these pathogenic
mechanisms are triggered early in infection may explain the varying
rates of disease progression among individuals.
It has been shown that the magnitude of immune activation
during HIV-1 infection is established early, is relatively stable over
time, and predicts the rate of disease progression better than viral
load (4, 5). Successful antiretroviral treatment (ART) of HIV-1–
infected individuals reduces viremia to undetectable levels, restores
CD4+ T-cell counts to some degree, and significantly prolongs
life (6). Despite this, ART does not fully restore immune func-
tion, and levels of residual immune activation are associated with
an increased risk of morbidity and mortality (7, 8). Moreover,
even with successful ART, the virus is not fully eradicated and
viral rebound occurs upon treatment interruption (9). Strategies
aimed at mitigating persistent immune activation and eradicating
the latent viral reservoir will contribute immensely toward im-
proving the quality of life of HIV-1–infected individuals and will
help to curb the epidemic. Thus, a better understanding of the
mechanisms driving HIV-1–induced immunological abnormalities
and the processes by which they ultimately cause disease is crucial
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for unveiling novel avenues for pursuing these more advanced
therapeutic interventions.
To date, research has primarily focused on identifying host
factors that contribute to viral control and favorable disease
outcomes, whereas viral characteristics have received less scrutiny
(10, 11). HLA class I alleles such as HLA-B*57 and B*5801 have
been shown to influence viral load and CD4+T-cell decline through
the induction of a strong CD8+ T-cell response that is able to target
functionally vulnerable regions of the genome such as the structural
protein Gag (10). The observation that not all individuals harboring
such protective HLA class I alleles go on to become long-term
nonprogressors suggests that other factors outside of host immu-
nogenetics play a role in defining disease progression (12). Trans-
mitted viral characteristics have been shown to impact viral load
within heterosexual transmission pairs, suggesting that viral char-
acteristics are heritable and can impact disease severity (11, 13, 14).
Moreover, we recently showed that attenuated viral replicative
capacity (vRC) of the transmitted virus, defined in vitro by the Gag
sequence, was associated with a significant delay in CD4+ T-cell
decline in individuals recently infected with HIV-1 subtype C (15).
Because this clinical benefit appeared to be partially independent
of set point viral load (SPVL), we hypothesized that high levels of
transmitted/founder virus replication might initiate irreversible
pathogenic events early in infection. Specifically, we hypothesized
that high vRC might lead to exacerbated immune activation, ele-
vated cellular dysfunction, and increased infection of memory CD4+
T-cell subsets, which in total might dictate the kinetics of sub-
sequent disease progression (15).
To test this hypothesis, we have studied a unique cohort of 127
Zambian seroconvertors acutely infected (median 46 d post-
infection) with HIV-1 subtype C that have up to 6 y of longitudinal
follow-up. We show here that transmission of high-vRC HIV-1 is
associated with a distinct inflammatory profile marked by signifi-
cantly higher levels of proinflammatory cytokines, increased cellular
immune activation and exhaustion, and higher levels of proviral
burden in naive and central memory CD4+ T-cell subsets at early
time points after infection. Thus, the replicative capacity of trans-
mitted HIV-1, defined by the structural protein Gag, is a critical
factor in defining early immune activation, the preservation or
loss of CD4+ T-cell homeostasis, and the subsequent trajectory
of disease progression. Interventions including early antiretroviral
therapy or vaccine-induced immunity that impact these early
events and that attenuate early viral replication will have a signif-
icant effect on the development of clinical disease.
Results
Viral Characteristics Determine HIV-1 Pathogenesis. Previously, our
work, and that of others, showed that transmitted viral character-
istics significantly correlate with early SPVL (11, 13, 14) as well as
CD4+ T-cell decline up to 3 y postinfection (15). Here, we sought
to determine the underlying mechanisms by which vRC of trans-
mitted HIV-1 impacts the trajectory of CD4 decline even in the
context of viral control by previously identified host factors, such as
protective HLA alleles, that also impact disease progression.
To assess the impact of the transmitted gag sequence on repli-
cative capacity, we amplified the gag gene from plasma virus
during acute infection time points (median 46 d after estimated
date of infection), generated replication-competent virus by clon-
ing the gag gene into a common proviral backbone (MJ4), and
measured vRC in an in vitro cell culture assay as described pre-
viously (15, 16). In comparing six Gag-MJ4 chimeric viruses to
transmitted/founder full-length infectious molecular clones de-
rived from the same individuals, we find a strong positive corre-
lation between the vRC of the chimeric viruses and the vRC of
the full-length infectious molecular clones (Fig. S1). This indi-
cates that although other genes undoubtedly play a role in defining
in vitro HIV-1 replicative capacity, the contributions of gag are
a significant component of the replicative capacity of the full-
length virus.
In this cohort of 127 acutely infected individuals from Zambia,
low vRC significantly delayed the time to CD4+ T-cell counts
<300 for up to 5 y postinfection (Fig. 1A, P = 0.002). The clearest
benefit is observed with the lowest vRC tercile compared with
the middle and highest tercile. A significant benefit remained
even down to CD4+ T-cell counts of <200, the clinical definition
of AIDS, when individuals infected with intermediate and highly
replicating viruses were combined into one group (Fig. 1B,
P = 0.03).
We have previously shown an association between early SPVL
and vRC (15). Thus, we sought to more definitively determine if
the replication capacity defined by the gag gene affected CD4
decline in a manner linked to, or independent of, the well-
documented effect of early SPVL on subsequent disease pro-
gression. In this cohort, we found SPVLs >105 RNA copies/mL
to be associated with poor outcomes for all volunteers (Fig. 1C,
P < 0.0001); however, vRC significantly dichotomized the trajectory
of CD4 decline (P < 0.0001) in individuals with SPVLs <105 (Fig.
1D), a majority (77%) of the cohort. This suggested inde-
pendent, but additive effects, of both vRC and early SPVL on
HIV disease progression. Moreover, whereas carriage of B*57/
B*5801 alleles protects against CD4 decline in this cohort (Fig.
1E, P = 0.006), vRC significantly dichotomizes disease trajecto-
ries of those with these protective HLA alleles (Fig. 1F, P =
0.04). This is confirmed in a multivariable Cox proportional
hazards model assessing the relative risk of vRC in the context of
other well-established predictors of HIV disease progression. We
find that low vRC, early SPVL, and canonical protective HLA
class I alleles (B*57, B*5801) were each highly significant in-
dependent predictors of CD4 decline (Table 1). Of note, the
protective effect of being infected with low-RC viruses as
opposed to high-RC viruses was similar to that of HLA-B*57
or B*5801 alleles, as evidenced by their similar hazard ratios
(Table 1).
Taken together, these data firmly establish vRC as a distinct
contributor to HIV disease progression. Moreover, they suggest
that vRC may modulate innate immune events very early after
infection, which could alter both the establishment of an in-
flammatory state and the development of an effective adaptive
immune response capable of controlling viremia. To further
test this hypothesis, we assessed early levels of circulating in-
flammatory cytokines, immune activation, and exhaustion in
T-cell compartments, as well as viral burden in different CD4+
T-cell subsets.
Viral Replicative Capacity Alters Early Inflammatory Cytokine Profiles.
Acute HIV infection is characterized by a rapid and robust ex-
pression of type I interferons (IFN-I), IFN-I–stimulated genes,
and inflammatory cytokines (17). Disruption of the gut-associated
lymphoid tissue (GALT) and subsequent microbial translocation
have also been shown to contribute significantly to this inflam-
matory state, possibly through a positive feedback loop (18). This
inflammatory response, particularly during chronic infection,
contributes to disease progression (19, 20). Therefore, we ana-
lyzed the levels of 16 inflammatory cytokines, chemokines,
and markers of gut damage and microbial translocation at or
before seroconversion to assess the effect of vRC on the early
inflammatory milieu [n = 33; previously dichotomized into low-
and high-vRC phenotypes (15)]. We found that vRC was posi-
tively correlated with a number of inflammatory cytokines (Table 2),
most notably IL-6 and IL-1β, two proinflammatory cytokines
previously implicated in driving aberrant CD4+ T-cell turnover
and impairing homeostatic proliferation (21). Of note, vRC was
also strongly correlated with elevated levels of IL-10, an im-
portant antiinflammatory cytokine linked to T-cell dysfunction in
HIV infection (22, 23).
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Because acute HIV-1 infection is associated with a complex
cytokine storm (17), we aimed to define distinct inflammatory
“profiles” that could explain the impact of vRC, by using an un-
supervised data reduction tool, principal component analysis
(PCA), which groups linear variables into combinations, termed
principal components (PCs) (Fig. 2A). Strikingly, principal
component 1 (PC1), which describes the greatest variation in the
dataset, significantly correlates with vRC, in that individuals with
positive loadings for PC1 (elevated levels of inflammation) tend
to have higher vRC, whereas those with negative loadings (low
levels of inflammation) are significantly enriched for poorly
replicating viruses (Fig. 2B, P = 0.0002). Moreover, principal
component 2 (PC2), which by definition is uncorrelated with
PC1, describes the second-greatest variation in the data and is
significantly correlated with SPVL (Fig. 2C, P = 0.01) but not
with vRC. The differences in analyte loadings between PC1 and
PC2 are shown in Fig. 2D, and the inflammatory cytokines that
substantially contribute to PC1 and -2 are depicted schematically
in Fig. S2. This result further highlights the independence of
factors associated with initial viral replication and subsequent
adaptive immune control of SPVL. Moreover, it demonstrates
that viruses with high vRC are correlated with a distinct in-
flammatory cytokine profile characterized by a heightened type I
and type II IFN response and elevated levels of key inflam-
matory cytokines such as IL-6 and IL-1β.
Replicative Capacity Is Associated with Levels of CD8+ T-Cell Activation
and Exhaustion. Chronic immune activation is a hallmark of HIV-1
infection; it often persists following ART and is a more reliable
predictor of disease progression than viral load (4, 5). Therefore, we
assessed the impact of vRC on levels of cellular immune activation
by measuring the coexpression of CD38 and HLA-DR on CD8+
T cells isolated within 3 mo postinfection for a subset of individuals
under study (n = 33). We found that vRC is positively correlated
with the expression of CD38 and HLA-DR on CD8+ T cells (Fig.
3A, P = 0.03). Consistent with previous studies (4, 24), we observe
that higher CD8+ T-cell activation in this cohort is associated
with faster CD4+ T-cell decline (Fig. 3E, P = 0.02), thus posi-
tioning T-cell activation as a link between vRC and subsequent
CD4+ T-cell decline.
In addition to cellular immune activation, CD8+ T-cell ex-
haustion is characteristic of pathogenic HIV/simian immunodefi-
ciency virus (HIV/SIV) infection. Exhaustion of CD8+ T cells is
marked by the increased expression of the inhibitory receptor,
programmed death 1 (PD-1), and levels of PD-1 expression predict
the rate of disease progression (25, 26). PD-1hi CD8+ T cells are
typically CD57low (25, 26); however, the contrasting PD-1lowCD57high
CD8+ T cells are more resistant to apoptosis (27). We find that
a greater percentage of CD8+ T cells isolated from individuals
infected with low-RC viruses displayed high levels of CD57 while
maintaining low levels of PD-1 (Fig. 3B, P < 0.0001) relative to
individuals infected by high-RC viruses. In CD8+ T cells, mark-
ers of exhaustion are often associated with impaired cytotoxic
function (28). Indeed, dual expression of granzyme B and per-
forin was positively correlated with the frequency of PD-1−/
CD57+ CD8+ T cells (Fig. 3C, P < 0.0001) and was inversely
correlated with vRC (Fig. 3D, P = 0.002). Consequently, we find
that PD-1 expression is associated with faster disease progression,
whereas CD57 expression is protective in terms of CD4+ T-cell
Fig. 1. HIV-1 replicative capacity, when defined by
the transmitted Gag sequence, is an independent
predictor of CD4+ T-cell decline in ART-naive, HIV-1–
infected individuals. Kaplan–Meier (KM) survival
analysis was performed to evaluate the effects of
viral and host factors on HIV-1 pathogenesis. End-
points were defined as CD4+ T-cell counts <300
(A and C–F) and <200 (B). (A) KM analysis demon-
strating the effect of in vitro vRC on CD4+ T-cell
decline. Low vRC, middle vRC, and high vRC repre-
sent the lowest, middle, and upper third of vRC
scores, respectively. (B) KM analysis demonstrating
the effect of low vRC on the time to end-stage dis-
ease or CD4+ T-cell counts <200. (C) KM analysis
demonstrating the effect of log10 increases in set
point VL on CD4+ T-cell decline. (D) KM analysis
demonstrating the additive effect of vRC and set
point VL on CD4+ T-cell decline. (E) KM analysis
demonstrating the effect of canonical protective
HLA class I alleles, B*57 and B*5801, on CD4+ T-cell
decline. (F) KM analysis demonstrating the effect
of vRC in individuals expressing protective HLA-B*57
or B*5801. All statistics were generated from the
log-rank test.















decline, in this cohort (Fig. 3 F and G; P = 0.05 and 0.04, re-
spectively).
It is important to point out that although CD8+ T-cell acti-
vation was also significantly correlated with VL measured at the
time the peripheral blood mononuclear cells (PBMCs) were
collected (P = 0.01, R2 = 0.18; Fig. S3A), which is consistent with
previous reports, the impact of VL on the reduction of either
CD8+ PD-1−/CD57+ cells (P = 0.03, R2 = 0.14; Fig. S3B) or
CD8+ granzyme B+/perforin+ cells (P = 0.02, R2 = 0.17; Fig.
S3C) was much less significant than the observed impact of vRC
on these parameters. Moreover, in a multivariate partial least-
squares regression analysis, in which both vRC and plasma VL
were important predictors of these CD8+ T-cell phenotypes,
vRC consistently had the greater influence (Fig. S3D). Thus,
reduced percentages of these potentially protective CD8+ cells
are not simply a function of antigen load as reflected by VL in
the plasma.
Taken together, these data suggest that individuals infected with
low-RC viruses mount a more functional and less exhausted cy-
totoxic T-lymphocyte (CTL) response early in infection that may
provide an extended clinical benefit for the individual.
Replicative Capacity Predicts Levels of CD4+ T-Cell Activation and
Proliferation. Immune activation in HIV-1 infection is associ-
ated with global immunological dysfunction, characterized by
increased cellular turnover and ultimately the disruption of
critical CD4+ T-cell homeostasis, indicative of progressive dis-
ease (29, 30). The percentages of CD4+ T cells expressing CD38/
HLA-DR and Ki67 were measured in PBMCs isolated less than
3 mo postinfection for a subset of individuals (n = 19, see Materials
and Methods for sample selection). Expression of these markers was
assessed on total CD4+ T cells as well as in the context of different
CD4+ T-cell subsets: naive (TN) (CD27
+, CD45RO−), central
memory (TCM) (CD27
+/−, CD45RO+, CCR7+), and effector
memory (TEM) (CD27
+/−, CD45RO+, CCR7−).
High vRC was associated with increased expression of CD38 and
HLA-DR on total (Fig. S4A, P = 0.02) and TEM (Fig. 4A, P = 0.02)
CD4+ T cells; however, this association was most pronounced in the
TCM (Fig. 4B, P = 0.006) compartment. Consistent with previous
reports (4, 31), high levels of CD4+ T-cell activation (CD38+/HLA-
DR+) are also associated with faster CD4+ T-cell decline (Fig. 4C,
P < 0.0001). Furthermore, individuals infected with high-RC viruses
exhibited a significantly greater percentage of CD4+ T cells
expressing Ki67. This association was most striking in the effector
memory T-cell subset (Fig. 4D, P = 0.003), but was also significant
for total (Fig. S4B, P = 0.008) and central memory CD4+ T cells
(Fig. 4E, P = 0.006). Increased CD4+ T-cell proliferation, demon-
strated by elevated expression of Ki-67 on CD4+ T-cell subsets,
was also associated with faster CD4+ T-cell decline, as has been
reported previously (Fig. 4F, P < 0.0001) (30, 32). Furthermore,
individuals infected with poorly replicating viruses displayed ex-
pression levels of CD38/HLA-DR and Ki67 on their CD4+ T cells,
which, although somewhat elevated, for the most part did not differ
significantly compared with those of HIV-uninfected Zambians
(Fig. 4 B, D, and E). Thus, these results suggest that, shortly
after transmission, individuals infected with low-vRC viruses
preserve an immune system more similar to that of a healthy
individual.
Despite the stratification of these individuals into those infected
with low- and high-RC viruses, an analysis of VL at the time these
PBMC samples were collected did not reveal any significant dif-
ference in mean VL between the two groups (mean VL for low
vRC = 4.5, mean VL for high vRC = 4.8; P = 0.26; Student’s t test).
Early Inflammatory Cytokine Profiles Associated with vRC Are Linked
to Activated T-Cell Phenotypes. To determine whether changes in T-
cell activation are associated with the distinct inflammatory cyto-
kine profiles associated with vRC, we compared individuals with
positive (increased inflammatory cytokine levels) and negative
loadings for PC1 (Fig. 2). Individuals with positive loadings for PC1
presented with significantly increased CD8+ T-cell activation (Fig.
5A, P < 0.0001) and exhaustion (Fig. 5 B and C, P = 0.002 and
0.005, respectively). Positive loadings were further associated with
increased frequency of PD-1+ CD4+ TCM cells (Fig. 5D, P = 0.01),
as well as higher levels of CD4+ TEM cell proliferation, as mea-
sured by Ki67 expression (Fig. 5E, P = 0.04). Thus, higher levels of
inflammatory cytokines are closely linked to the activated,
exhausted T-cell phenotypes observed in individuals infected with
high-RC viruses.
High vRC Is Associated with Increased Proviral Burden in CD4+ T-Cell
Subsets. Establishment of the latent HIV reservoir occurs early
during acute infection and sets the stage for viral persistence.
Thus, even in the context of suppressive antiretroviral therapy,
HIV-1 cannot be fully eradicated (9, 33, 34). To determine
whether the replicative capacity of the transmitted/founder virus
influences the proviral DNA burden during early infection, levels
of cell-associated viral DNA were measured in naive, central
memory, and effector memory CD4+ T-cell subsets sorted from
PBMCs isolated 3 mo postinfection (n = 21). Despite no signifi-
cant difference in mean VL between the two groups at this time
point (mean VL for low vRC = 4.4, mean VL for high vRC = 4.8;
Table 1. Host and viral characteristics independently predict
CD4+ T-cell decline
Cox proportional hazards model,* time
to CD4 <300
Factors tested HR 95% CI P value
Female 1.10 0.67–1.70 0.78
Low vRC, lowest tercile 0.48 0.28–0.80 0.004
B*57/5801 0.45 0.23–0.81 0.006
Set point VL† 10.00 2.86–44.1 0.0004
CI, confidence interval; HR, hazard ratio.
*Multivariable Cox proportional hazards model with an endpoint defined
as a single CD4+ T-cell count reading below 300 (n = 127).
†Set point VL was defined as the earliest nadir viral load, between 3 mo
and 9 mo postinfection, which remained stable for subsequent viral load
readings.
Table 2. High vRC is associated with significantly increased





mean pg/mL P value‡
IL-6 1.88 3.94 0.004
IL-10 5.5 10.73 0.004
IL-1β 0.21 0.57 0.008
IFNγ 4.38 10.26 0.014
IP-10 639.56 1,108.43 0.018
TNFα 10.76 13.87 0.028
IL-7 1.81 2.65 0.046
IFNα2 21.09 31.48 0.048
*Low vRC was defined as the lowest third of all replicative capacity scores in
the larger cohort of 127 seroconvertors. Of this lowest third, 12 were ran-
domly selected and analyzed for the presence of 16 analytes associated with
inflammation.
†High vRC was defined as the upper two-thirds of all replicative capacity
scores in the larger cohort of 127 seroconvertors. Of this upper two-thirds,
21 were randomly selected and analyzed for the presence of 16 analytes
associated with inflammation.
‡P values were generated using Student’s t test and reported P values are
one tailed.
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P = 0.13; Student’s t test), we observed that high vRC was asso-
ciated with a significant increase in the amount of cell-associated
viral DNA in both TCM (P = 0.01) and TN (P = 0.001) CD4
+
subsets (Fig. 6A). Because high vRC was associated with in-
creased levels of immune activation and proliferation, we sought to
determine whether a direct association exists between these
markers and the magnitude of viral burden in TCM, a key pop-
ulation in CD4+ T-cell homeostasis. We find that HIV-1 DNA in
TCM positively correlates with expression of CD38
+/HLADR+ on
TEM (Fig. 6B, P < 0.0001) and, to a lesser extent, on TCM (R
2 = 0.3,
P = 0.01). Similarly, HIV-1 DNA in TCM was positively correlated
with Ki67 expression on TEM CD4
+ cells (Fig. 6C, P = 0.0009).
Moreover, higher levels of cell-associated HIV DNA in central
memory CD4+ T cells were associated with an accelerated loss of
CD4+ T cells (Fig. 6D, P = 0.01).
Discussion
Recent studies have implicated transmitted viral characteristics
in explaining the heritability of HIV-1 pathogenesis (11, 15, 35),
and the results delineated above argue that a major component
of this heritability is the replicative capacity of the transmitted/
founder virus. Moreover, in this cohort of Zambian seroconvertors,
acutely infected with HIV-1 subtype C, we demonstrate that vRC
is a key contributor to CD4+ T-cell decline that can only be
modulated but not reversed by the protective effects of HLA
class I alleles such as B*57 and B*5801. This role in disease
pathogenesis is consistent with studies of the lymphocytic cho-
riomeningitis virus (LCMV) infection model, where the higher
replicative capacity LCMV clone 13 strain goes on to induce
chronic infection whereas the more attenuated Armstrong strain
is quickly contained by the immune system (36). Although we
were unable to accurately measure peak viral load in this cohort
of HIV-1 acutely infected individuals, it seems likely that viruses
with high replicative capacity have the potential to induce much
higher levels of peak viremia, which then induces exacerbated
immunopathology that cannot be completely reversed by the
immune response. Thus, it is clear that early interactions be-
tween the virus and the host have the potential to set in motion
a series of events that ultimately define the trajectory of disease
progression.
The first interactions between HIV-1 and the host immune
response occur at the interface of the virus and the innate im-
mune system. Viral replication results in an initial cytokine storm
that is thought to be largely deleterious (17). We show here that
the replicative capacity of HIV-1 modulates the magnitude and
composition of the early inflammatory milieu, perhaps through
differential activation of innate sensing mechanisms that lead to
multiple inflammatory consequences. Notably, the inflammatory
state associated with high vRC is characterized by elevated levels
of key mediators, such as IFNα, IL-1β, and IL-10, which are
known to drive pathogenesis (37).
Elevated levels of IFNα can be detected in HIV-infected
individuals as early as 6 d after the presence of detectable plasma
viremia (17). As the first plasma samples available for analysis in
this cohort were collected a median of 46 d postinfection, our
measurements most likely reflect the contraction phase. It is
reasonable to postulate that in HIV-1 infection the degree of this
contraction could significantly affect severity of disease. This is
supported by data from the SIV model, where robust expression
of IFN-stimulated genes (ISGs) is observed in both natural SIV
infection of sooty mangabeys and pathogenic infection of rhesus
macaques, but where expression of these ISGs is quickly resolved
in sooty mangabeys by an active down-regulation process (38).
Our data show that individuals infected with highly replicating
viruses are less able to resolve acute levels of IFNα (and by ex-
tension, ISGs) by the time of seroconversion, consistent with
what is observed in pathogenic SIV infection.
Additionally, vRC was positively correlated with levels of IL-1β,
a highly inflammatory cytokine associated with pyroptosis, an
inflammatory form of programmed cell death recently linked to
abortive HIV infection of quiescent CD4+ T cells (39). It is likely
that increased viral production during the acute phase of HIV-1
infection increases the occurrence of abortive infection. This
would escalate pyroptotic cell death, drive the production and
release of IL-1β, and serve to foment immune activation and
exacerbated immunopathology.
Fig. 2. High vRC is associated with a distinct cyto-
kine profile early in infection, characterized by ele-
vated levels of inflammatory cytokines. Principal
component analysis (PCA) was used to reduce
dimensionality and extract principal components
composed of linear combinations of 16 different
analytes measured at the seroconversion time point
(n = 33). (A) Principal component 1 (PC1) and prin-
cipal component 2 (PC2) scores are depicted in a
two-dimensional scatter plot for each individual.
The first principal component (x axis), which describes
the greatest variation in the dataset, has positive
loadings associated with an increased production of
key inflammatory cytokines. Red, individuals with
high vRC; blue, individuals with low vRC. (B and C)
Associations between vRC and PC1 loadings (B) and
early set point VL and PC2 loadings (C). (D) Bar graph
depicting analyte loadings for PC1 (black) and PC2
(gray). Loadings were extracted from the PCA corre-
lation matrix and represent the degree of contribu-
tion of each analyte to both principal components.
Positive loadings for PC1 are characterized by in-
creased levels of key inflammatory cytokines, such as
IL-6 and IL-1β, as well as increased production of type I
(IFNα2) and type II (IFNγ) interferons. Positive loadings
for PC2 are characterized by increased levels of IP-10
and MCP-1 and decreased levels of MIP-1β. Statistical
comparisons were made using Student’s t test. P val-
ues are one tailed.















Enhanced production of IL-10 was also observed in individuals
infected with high-RC viruses. Although IL-10 is traditionally
seen as an antiinflammatory cytokine capable of reducing inflam-
mation, in this setting it may be a surrogate of hyperactivation of
the innate immune response. Previous studies demonstrated that
increased PD-1 expression by monocytes, due to the presence
of microbial products and inflammatory cytokines in HIV-1 in-
fection, can lead to the production IL-10, which further disrupts
T-cell function (23). Moreover, IL-10 blockade restored the
antigen-induced proliferation of HIV-specific CD4+ and CD8+ T
cells in vitro, as well as the production of effector cytokines by
HIV-specific CD4+ T cells (22). Thus, in the present study, en-
hanced IL-10 production may reflect a dysregulated innate and
adaptive immune response brought on by intensified viral rep-
lication during acute infection.
Previous studies showed that the level of immune activation is
established very early after HIV-1 infection and predicts disease
progression even when viral loads are suppressed either im-
munologically or by ART (4, 5, 8). For the first time to our
knowledge, we demonstrate that levels of aberrant immune ac-
tivation in CD8+ and CD4+ T cells can be significantly attributed
to the replicative capacity of the transmitted virus. We further
link the increased activation, exhaustion, and proliferation of
T cells to inflammatory cytokine profiles, suggesting a mecha-
nism by which vRC, through induction of an early innate immune
response, influences levels of chronic cellular immune activation.
This is supported by previously reported associations between
CD8+ T-cell activation and the presence of inflammatory cyto-
kines (40, 41).
Whether the elevated inflammatory response and exacerbated
immunopathology associated with highly replicating viruses are
the consequence of molecular signatures specific to Gag and
TRIM5 sensing (42) or higher overall antigen load remains to be
determined. Increased vRC likely results in elevated levels of
Fig. 3. High vRC is associated with increased CD8+
T-cell activation and lower cytotoxic potential. (A–D)
Cryopreserved PBMCs were collected less than 3 mo
after the estimated date of infection (n = 33) and
stained with two multicolor flow cytometry panels
evaluating either memory subsets and markers of
cellular activation and exhaustion (A and B) or
markers of T-cell cytotoxicity (C and D). (A) Corre-
lation between vRC and the percentage of total
CD8+ T cells coexpressing CD38 and HLA-DR.
(B) Correlation between vRC and the percentage
of CD8+ T cells that are CD57+ but remain PD-1−.
(C) Association between the percentages of PD-1−/
CD57+and granzyme B+/perforin+ CD8+ T cells.
(D) Correlation between cytotoxic potential in CD8+
T cells, as measured by coexpression of granzyme B
and perforin, and vRC. Correlation statistics were
generated using linear regression. Solid lines in-
dicate trend lines, and dashed lines represent
95% confidence bands. (E–G) Kaplan–Meier survival
curves depict associations between markers of cel-
lular activation and risk for CD4+ T-cell decline, de-
fined as the time to CD4+ T-cell counts <300. Kaplan–
Meier survival statistics were generated from the
log-rank test.
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HIV-1 epitope presentation and recognition by CTLs, which in
turn could lead to aberrant T-cell activation via T-cell receptor
(TCR) overstimulation (43). In support of this hypothesis, we
found vRC to be positively correlated with PD-1 expression on
CD8+ T cells. Because PD-1 expression in chronic HIV infection
has previously been shown to be most pronounced on HIV-
specific CD8+ T-cell populations (25, 26), this is consistent with
increased circulating antigen being a factor linking vRC to in-
creased markers of immune activation and exhaustion in the
CD8+ T-cell compartment. It is important to note, however, that
loss of protective CD8+ PD-1−/CD57+ cells at these early time
points is strongly associated with increasing vRC and to a lesser
degree with contemporaneous VL, suggesting that it is not sim-
ply antigen load that defines this pathogenic effect. A key factor
governing this observation may be that vRC is a heritable char-
acteristic of the virus that remains relatively stable at these early
times after infection, whereas, in contrast, VL is in significant
flux due to the onset of the adaptive immune response. Thus,
vRC, as a measurable phenotypic trait, may provide a correlate
of viral damage to the immune system in tissues or at even earlier
times where and when VL is difficult to measure.
Finally, we demonstrated that the amount of HIV-1 DNA
harbored by both TCM and naive (CD27
+/CD45RO−) CD4+
T cells is highly associated with viral replicative capacity. It is
possible that the increased levels of HIV-1 DNA found in the
“naive” CD4+ T cells could be due in part to the presence of
T memory stem cells (TSCM) that would be found within
our sorted naive T-cell populations (44, 45). These long-lived
memory T cells with stem cell-like properties are susceptible to
HIV-1 or SIV in pathogenic infections but are spared in non-
pathogenic SIV disease (46). Similarly, the long-lived TCM CD4
+
cells are spared in nonpathogenic SIV infection, and infection of
this subset has been linked to the immunopathology of HIV-1
infection (30, 47). Moreover, recent evidence demonstrates that
reduced infection of TSCM and TCM CD4
+ cells is associated with
a nonprogression phenotype in viremic individuals (48). The
results of the present study provide further evidence that HIV-1
infection of these cell types occurs early, is linked to increased
CD4+ T-cell activation, and in TCM significantly predicts disease
progression, perhaps by disrupting the capacity to renew the
CD4+ TEM population (30). TCM CD4
+ cells have also been
highlighted as an integral population for the maintenance of
latency and viral persistence (33). Our findings suggest that the
extent to which HIV infects this population and establishes a
latent reservoir might be influenced by characteristics of the
transmitted/founder virus.
Fig. 4. Viral RC is associated with increased cellular activation and proliferation in CD4+ T-cell memory subsets. Cryopreserved PBMCs isolated at 3 mo after
the estimated date of infection from individuals with high vRC (n = 13) and low vRC (n = 6) as well as cryopreserved PBMCs from HIV-negative Zambians (n =
14) were stained for markers of activation and cellular turnover and for delineation of memory T-cell subsets. Statistical comparisons were made using the
Student’s t test. (A and B) Comparison of the percentage of CD4+ TEM (A) and TCM (B) coexpressing the activation markers CD38 and HLA-DR in HIV-negative
Zambians and individuals infected with either low-RC or high-RC viruses. (D and E) Comparison of the percentage of CD4+ TEM (D) and TCM (E) positive for Ki67
in HIV-negative Zambians and individuals infected with either low-RC or high-RC viruses. (C and F) Kaplan–Meier survival analyses (with an endpoint defined
as CD4+ T-cell counts <300) depict associations between the percentage of memory CD4+ T cells expressing markers of activation (C) and proliferation (F) and
the decline in total CD4+ T cells. Kaplan–Meier survival statistics were generated from the log-rank test.















Taken together, these results support an unprecedented role for
the viral replicative capacity of the transmitted/founder virus, in
determining the early inflammatory state and general immune
dysfunction of HIV-1–infected individuals as well as their sub-
sequent disease trajectory. The data presented here suggest that
viral characteristics can provide independent information about an
individual’s risk for disease progression and point to a previously
unidentified target for interventions to reduce immune activation
and viral burden. Vaccine-induced immune responses or
interventions that effectively attenuate vRC in the earliest stages
of infection could not only have a dramatic impact on viral
control and disease progression, but, based on our recent find-
ings (35) also impact the efficiency of subsequent transmission to
other partners. Moreover, reducing the size of the viral burden in
key T-cell populations before antiretroviral treatment could
augment cure strategies aimed at eliminating the latent reservoir.
Fig. 5. Inflammatory cytokine profiles associated with vRC correlate with T-cell activation. Inflammatory cytokines measured at seroconversion in 33 acutely
infected individuals were used to define distinct cytokine profiles via principal Component Analysis (Fig. 2). In this group of 33 individuals, a subset of 18 and
19 individuals had also been immunophenotyped for CD8+ and CD4+ T-cell activation, respectively. Positive loadings (elevated inflammatory cytokines) were
defined as a PC1 score >0 and negative loadings were defined as a PC1 score <0. (A–C) The differences in CD8+ T-cell activation in individuals with positive
(elevated inflammatory cytokines) or negative loadings for PC1. (D and E) The differences in CD4+ T-cell activation in individuals with positive (elevated
inflammatory cytokines) or negative loadings for PC1. The left-hand y axis displays the percentage of positive cells for A–D; the right-hand y axis displays the
percentage of Ki67+ cells for E. (*P < 0.05, **P < 0.01, ***P < 0.001; statistical comparisons were made using Student’s t test, P values are one tailed.)
Fig. 6. Viral RC correlates with the burden of HIV-1 viral DNA in CD4+ TCM and TN. (A) Cryopreserved PBMCs isolated 3 mo postinfection (n = 21) were stained
for markers to delineate memory phenotypes, and CD4+ T cells were sorted into three distinct populations, TN (CD27
+, CD45RO−), TEM (CD27
+/−, CD45RO+,
CCR7−), and TCM (CD27
+/−, CD45RO+, CCR7+). Cell-associated HIV-1 DNA was quantified by real-time PCR amplification of the HIV-1 subtype C integrase gene.
Cell copy number was normalized based on real-time PCR amplification of the human albumin gene. (A) Bar graphs depicting the magnitude of viral burden
in TN, TCM, and TEM between individuals infected with either low-RC or high-RC viruses. (B and C) In a majority of the same individuals (n = 18), a fraction of
unsorted PBMCs were stained for markers of cellular activation and proliferation. (B) Correlation between the magnitude of viral burden in CD4+ TCM and the
percentage of activated (CD38+/HLA-DR+) CD4+ TEM. (C) Correlation between the magnitude of viral burden in CD4
+ TCM and the percentage of proliferating
(Ki67+) CD4+ TEM. Correlation statistics were generated using linear regression. Solid lines indicate trend lines, and dashed lines represent 95% confidence
bands. (D) A Kaplan–Meier survival analysis (with an endpoint defined as CD4+ T-cell counts <300) depicts the effect of viral burden in CD4+ TCM on total CD4
+
T-cell decline. Kaplan–Meier survival statistics were generated from the log-rank test.
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Materials and Methods
Study Subjects.All participants in the Zambia EmoryHIVResearchProject (ZEHRP)
discordant couples cohort in Lusaka, Zambia were enrolled in human subjects
protocols approved by both the University of Zambia Research Ethics Committee
and the Emory University Institutional Review Board. Before enrollment, indi-
viduals received counseling and signedawritten informed consent formagreeing
to participate.
The subjects included in this study were selected from the ZEHRP cohort
based on being recently infected with HIV-1. All subjects were initially se-
ronegative partners within serodiscordant cohabitating heterosexual couples
that subsequently seroconverted. All subjects were antiretroviral therapy
naive and were identified a median of 46 (interquartile range = 33–49)
d after the estimated date of infection (EDI). The algorithm used to de-
termine the EDI has been previously described (49). All subjects were
infected by HIV-1 subtype C viruses.
Generation of Gag-MJ4 Chimeras and Transmitted/Founder Full-Length Infectious
Molecular Clones. Gag-MJ4 chimeras were generated from frozen plasma iso-
lated at the seroconversion time point for 127 subjects as previously described
(15, 16). Briefly, nested PCR primer sets were used to amplify the gag gene from
patient plasma and cloned into the MJ4 provirus, using a restriction enzyme-
based approach. Replication-competent virus was generated by transfection of
293T cells with proviral plasmids, and infectious units were assessed on the
TZM-bl indicator cell line. GXR25 cells were infected at a constant multiplicity of
infection of 0.05, and viral production in the supernatant was evaluated using
a radiolabeled reverse transcriptase assay at days 2, 4, and 6 postinfection.
Replication capacity scores were generated by dividing the log10-transformed
slope of replication from days 2–6 for each Gag-MJ4 chimera by the log10-
transformed slope of replication of wild-type MJ4. The sequences of the cloned
gag genes are available at GenBank under accession nos. KP715723–KP715849.
Full-length genome cDNA synthesis and near full-length single genome
amplification were performed as described previously (50) on seroconversion
plasma samples for six individuals where Gag-chimera vRC had been mea-
sured. Sequencing of multiple amplicons allowed for confirmation of single-
variant transmission by star-like phylogeny and to infer the near full-length
sequence of the transmitted/founder (TF) virus. Full-length genome in-
fectious molecular clones of the entire TF sequence were constructed as
described previously (50). Viral stocks were generated and infectious units
assessed in the same way as Gag-MJ4 chimera viruses. Replication curves
were generated by infecting PHA-stimulated PMBCs at a constant multi-
plicity of infection of 0.01. Viral output was assessed at days 0, 2, 4, 6, and 8 d
postinfection via a radiolabeled reverse transcriptase assay, and replication
scores were generated in the same way as for Gag-MJ4 chimeras.
Evaluation of Plasma Cytokines. Plasma levels of cytokines and chemokines were
measured using MILLIPLEX Human Cytokine/Chemokine detection kits (Milli-
pore). High sensitivity kits were used formeasurement of IFNγ, IL-1β, IL-6, and IL-7
and regular sensitivity kits were used for IFNα2, IL-10, IP-10, MCP-1, MIP-1β, and
TNFα and were used according to the manufacturer’s instructions. Samples were
run in duplicate with all individuals on the same plate and wells with low bead
count or coefficient of variance >30% were excluded from subsequent analysis.
Plates were read on the Bio-Plex 3D Suspension Array System (Bio-Rad). Levels of
sCD14 (R&D Systems), CRP (Millipore), sCD163 (Trillium Diagnostics), and D-dimer
(American Diagnostica) were all measured using standard ELISA-based assays
according to the manufacturer’s instructions. Measurement of LPS levels was
performed using the LAL Chromogenic Endotoxin Quantification kit (American
Diagnostica). Intestinal fatty acid binding protein (I-FABP) was measured using
a commercially available ELISA DuoSet assay (R&D Systems) according to the
manufacturer’s instructions with minor adjustments. Plasma samples were di-
luted to 10% (vol/vol) in diluent from the R&D Systems soluble CD14 ELISA kit
(DC140) and plates were blocked with Sigma Blocking Buffer.
Flow Cytometry Analysis. Cryopreserved PBMCs isolated from 33 HIV-1–
infected Zambians at a median of 49 d after the estimated date of infection
were analyzed by flow cytometry to immunophenotype CD8+ T cells. The
12-parameter cytometric staining panel is depicted in Table S1. Frozen
PBMCs were thawed, washed once with R20 [RPMI 1640 (Sigma) containing
20% FCS (Sigma), 1% 1 M Hepes buffer (Sigma), 1% L-glutamine (Sigma), 1%
penicillin–streptomycin (Sigma), and 1% sodium pyruvate (Sigma)], and then
rested overnight in 4 mL of R20 at 37 °C, 5% CO2, 95% humidity.
For each individual, 106 PBMCs per well were washed once with PBS
(Sigma) before staining. When evaluating markers of T-cell cytotoxicity, an
11-parameter cytometric panel, shown in Table S2, was used. For the in-
tracellular markers granzyme B and perforin, Cytofix/Cytoperm (BD) was
used for permeabilization and staining per the manufacturer’s protocol.
CD4+ T-cell memory populations and markers of activation and pro-
liferation were analyzed in a separate flow analysis, using a 12-parameter
cytometric panel shown in Table S3. Cryopreserved PBMCs isolated from
a subset of 19 HIV-1–infected Zambians at 3 mo postseroconversion as well
as 14 uninfected healthy Zambians were assessed for activation and pro-
liferation, using 12-parameter flow cytometric analysis. The individuals
were chosen based on replication capacity phenotype, overlap with other
parameters measured, and the sample availability at this time point.
Approximately 20 million PBMCs from each individual were first thawed
and then washed twice with 10mL of complete RPMI supplemented with 2 μL
of DNase. Once the cells were counted using an automated cell counter,
∼2 million cells were set aside for staining with the above 12-parameter
panel, and the rest of the cells were used for sorting if they were derived
from an HIV-1–infected individual (see below for further methods on sort-
ing). Cells were then washed with 3 mL of Dulbeco’s PBS without Ca+/Mg+
(Invitrogen) and stained for 5 min at room temperature with Aqua Live/
Dead amine dye-AmCyan (Invitrogen). Anti-CCR7-PE-CY7 was added to the
cells and incubated at 37 °C for 15 min. The rest of the monoclonal anti-
bodies were then added and incubated at room temperature for 30 min
(without anti-Ki67). The cells were then permeabilized and stained for the
intracellular marker Ki67 for 30 min at room temperature, using the BD
perm/wash kit (Fisher) following the manufacturer’s directions.
All flow cytometry data were collected on an LSRII cytometer with
FACSDiVa Version 6.1.3 software. Analyses of these data were performed
using FlowJo Version 9.7.5 software (TreeStar).
Detection of Cell-Associated HIV-1 Viral DNA in CD4+ T-Cell Compartments.
Cryopreserved PBMCs isolated from a subset of 21 HIV-1–infected individu-
als at 3 mo postseroconversion were stained to delineate memory CD4+
T-cell subsets, using the seven-parameter cytometric panel displayed in Table
S4. Samples were sorted into naive CD4 T cells (CD3+, CD4+, CD8−, CD27+,
CD45RO−), central memory CD4 T cells (CD3+, CD4+, CD8−, CD27+/−, CD45RO+,
CCR7+), and effector memory CD4 T cells (CD3+, CD4+, CD8−, CD27+/−, CD45RO+,
CCR7−), using a FACSAria II flow cytometer (Becton Dickinson). Sorted pop-
ulations were checked for purity and were found to be between 94.5% and
99.4% specific for the population desired.
Live, sorted CD4+ T-cell subsets were immediately lysed and genomic DNA
was extracted using the DNeasy Blood & Tissue Kit (Qiagen). Samples were
eluted in nuclease-free water and analyzed for DNA concentration. DNA
samples were analyzed by quantitative real-time PCR (qPCR) for total cell-
associated HIV DNA. Approximately 10,000 cell equivalents of genomic DNA
were loaded in a 50-μL qPCR reaction, using a custom-designed HIV clade
C primer and probe set designed to detect HIV int sequences derived from the
patient population. Albumin was used as an internal control to quantify the
number of genomes present. Both HIV and albumin absolute copies were
determined using an external standard curve. HIV clade C primer and probe
sequences are Fwd 5′-GTTATYCCAGCAGARACAGG-3′, Rev 5′-TGACTTTGRG-
GATTGTAGGG-3′, and probe 5′-RGCAGCCTGYTGGTGGGC-3′. Human albumin
primer and probe sequences are Fwd 5′-TGCATGAGAAAACGCCAGTAA-3′, Rev
5′-ATGGTCGCCTGTTCACCAA-3′, and probe 5′-FAM-TGACAGAGTCACCAAA-
TGCTGCACAGAA-3′. qPCRs were performed using the Taqman Universal
master mix (Life Technologies), 0.2 μM of each primer, and 0.125 μM of probe.
All assays were performed on the ABI 7500 system (Life Technologies).
Statistical Analyses. All statistical analysis was performed using JMP, version
11 (SAS Institute). All bivariate continuous correlations were performed using
standard linear regression. One-way comparison of means was performed
using Student’s t test, and one-tailed P values are reported. Kaplan–Meier
survival curves and Cox proportional hazards models were performed using
an endpoint defined as a single CD4+ T-cell count reading less than 300,
unless otherwise specified, and statistics reported for survival analyses were
generated from the log-rank test.
PCA was performed using the JMP version 11 statistical package. Extreme
positive values for each of the 16 analytes measured in plasma were Win-
sorized to the 90th percentile. Missing values were imputed using multiple
linear regression models, and individuals for whommore than three cytokine
values were missing were excluded. All 16 analytes that were measured in 33
individuals were used to extract latent variables.
Depiction of cytokine loadings for PC1 and PC2 (Fig. S2) was generated
using Cytoscape v3.0. The loading matrix (list of pairwise correlations be-
tween each latent variable and each of the 16 analytes tested) was extracted
from the PCA and used to represent the strength of contribution of each
analyte to either PC1 or PC2.















Multivariate partial least-squares regression portraying the independent
contributions of vRC and VL to CD8+ T-cell activation phenotypes (Fig. S3D)
was performed with JMP version 11, using the SIMPLS algorithm and K-fold
cross validation, where K = 7.
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